In the front line setting, both inhibitors have also demonstrated clinical effectiveness [33, 34], leading to FDA approval of ivosidenib for patients with newly diagnosed IDH1 mutated AML based on an ORR of 42% (CR: 30%) with median OS of 12.6 months in older patients not eligible for intensive therapy [34]. The gene discussed is IDH1; the disease is acute myeloid leukemia.